Abstract:Abstract Background Blood based biomarkers for Alzheimer’s disease (AD) are becoming increasingly promising. Although plasma amyloid-β (Aβ) and total tau (t-tau) showed a potential ability in identifying cerebral amyloid deposition and AD. Comparisons of these plasma biomarkers along with Aβ-PET in a cohort of normal controls (NC), subjective cognitive decline (SCD), objectively-defined subtle cognitive decline (Obj-SCD), mild cognitive impairment (MCI) and AD remained lacking. Methods A total of 407 individuals aged from 40 to 90 years old were recruited, including 76 of NC, 77 of SCD, 61 of obj-SCD, 92 of MCI and 101 of AD. Plasma Aβ40, Aβ42 and t-tau were examined via single-molecule array (Simoa) immunoassay. A subset of 132 individuals underwent cerebral amyloid scans with 18F-florbetapir PET. Comparisons of plasma t-tau, Aβ40, Aβ42 and Aβ42/Aβ40 ratio were conducted between different diagnostic groups and cerebral Aβ burdens. Pearson correlation analysis was used to evaluate the correlation between Aβ42, Aβ42/Aβ40 ratio and 18F-florbetapir SUVR. Receiver operating characteristic (ROC) curve analyses were carried out to evaluate the capacity of plasma biomarkers in identifying high brain Aβ burden and diagnosis of AD. Results Plasma Aβ42 was significantly higher in SCD and obj-SCD than NC, MCI and AD. Plasma Aβ40 was significantly higher in SCD and obj-SCD than NC and AD. The lowest levels of plasma Aβ42 and Aβ42/Aβ40 ratio were found in AD. No significant difference of plasma t-tau was found among groups. Plasma Aβ42 and Aβ42/Aβ40 ratio were inversely correlated with 18F-florbetapir SUVR (r=-0.272, P = 0.003; r=-0.211, P = 0.021 respectively). Aβ42/Aβ40 ratio performed well in predicting high brain Aβ burden (area under the curve, AUC = 0.762). Plasma Aβ42 and Aβ42/Aβ40 ratio had acceptable diagnostic accuracy for AD (AUC = 0.714 and 0.706 respectively), even in Aβ-PET (+) individuals (AUC = 0.728 and 0.808 respectively). Conclusions Plasma Aβ40 and Aβ42 measured by Simoa immunoassay showed a significantly bidirectional trend of initially increasing from NC to SCD and obj-SCD, and then declining to MCI and AD. In addition, plasma Aβ was significantly correlated with 18F-florbetapir PET SUVR and showed potential value in predicting cerebral Aβ deposition and risk of AD.

Subsequent correlated changes in complement component 3 and amyloid beta oligomers in the blood of patients with Alzheimer's disease

Alzheimer's disease-associated complement gene variants influence plasma complement protein levels

Serum levels of complement C3 and Aβ1-42 in patients with Alzheimer disease

Plasma Complement C3 Levels in Alzheimer's Disease

CSF complement proteins are elevated in prodromal to moderate Alzheimer's disease patients and are not altered by the anti‐tau antibody semorinemab

High Correlation among Brain-Derived Major Protein Levels in Cerebrospinal Fluid: Implication for Amyloid-Beta and Tau Protein Changes in Alzheimer’s Disease

Correlation of blood–brain barrier leakage with cerebral small vessel disease including cerebral microbleeds in Alzheimer's disease

High complement levels in astrocyte-derived exosomes of Alzheimer disease

Non-linear Character of Plasma Amyloid Beta Over the Course of Cognitive Decline in Alzheimer’s Continuum

Oligomeric forms of amyloid-β protein in plasma as a potential blood-based biomarker for Alzheimer’s disease

Changes of plasma Aβ and t-tau along with 18F-florbetapir PET in a cohort of cognitive decline

Plasma amyloid-beta oligomer is related to subjective cognitive decline and brain amyloid status

CSF 14-3-3β is associated with progressive cognitive decline in Alzheimer's disease

Proteome-wide analysis identifies plasma immune regulators of amyloid-beta progression

Analysis of Complement System and Its Related Factors in Alzheimer’s Disease

Follow-up Comparisons of Two Plasma Biomarkers of Alzheimer's Disease, Neurofilament Light Chain, and Oligomeric Aβ: A Pilot Study

Alzheimer Disease Cerebrospinal Fluid Biomarkers in a Tertiary Neurology Practice

Diagnostic Blood Biomarkers in Alzheimer’s Disease

Correlations between plasma markers and brain Aβ deposition across the AD continuum: Evidence from SILCODE

[O1–14–03]: THE ROLE OF COMPLEMENT C3 AND C3AR RECEPTOR IN TAU PATHOLOGY IN ALZHEIMER's DISEASE

Aβ oligomers peak in early stages of Alzheimer's disease preceding tau pathology